Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on August 3, 2020, regarding events occurring on that date. The Company is a Delaware corporation incorporated as an emerging growth company, with its principal executive offices located in South San Francisco, California. The report primarily addresses the closing of a private placement transaction.
Key Financial Metrics
The filing details a specific capital raise event rather than providing comprehensive financial statements for a reporting period.
- Transaction Type: Unregistered sale of equity securities (Private Placement).
- Investor: Glaxo Group Limited (GSK).
- Shares Issued: 1,333,333 shares of common stock.
- Price Per Share: $15.00.
- Gross Proceeds: Approximately $20.0 million.
- Closing Date: August 3, 2020.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The material change reported is the increase in the Company's equity capital and cash reserves resulting from the private placement with GSK. This transaction was executed under a Stock Purchase Agreement entered into on June 17, 2020. The shares were sold pursuant to exemptions under Section 4(a)(2) of the Securities Act and Regulation D, as GSK represented it is an accredited investor acquiring the shares for investment purposes only.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The primary contingency noted is that the shares issued in this private placement are not registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the dilution impact of the 1,333,333 newly issued shares on existing shareholders.
- Confirm the use of the approximately $20.0 million in gross proceeds as disclosed in subsequent filings or the press release (Exhibit 99.1).
- Review the full text of the Stock Purchase Agreement to understand any specific terms or restrictions associated with GSK's investment.
- Check for any lock-up agreements or resale restrictions applicable to the shares sold to GSK.